Wednesday, 17 Oct 2018

You are here

High Biologic Blood Levels Increases the Risk of Infections in RA

A big concern of most is the risk of infection with use of tumour necrosis factor inhibitor (TNFi) and biologic drugs.  While studied in both trials and in post-marketing studies, it is unknown if infection risk is dose-dependent.

In abstract OP0229 UK researchers have shown high biologic blood levels are associates with an increased risk of total infections in RA, but not serious infetions.

They merged data from two large British RA registries (British Society for Rheumatology Biologics Register-RA [safety data] and the Biologics in RA Genetics and Genomics Syndicate [serological samples]) to assess the effect of biologic drug levels in rheumatoid arthritis (RA) patients on all infections (AI) and SI (infections requiring hospitalisation, IV antibiotics or lead to death.

Serum samples and drug levels were measured at 3, 6,  and 12 months after biologic initiation and the risk of first and total infections within the first year was analysed.

The RA population (n=703) of predominantly female patients on biologics  - 286 etanercept, 179 adalimumab, 120 certolizumab, 104 tocilizumab and 14 infliximab were studied. The majority of enrolled patients were on their first biologic (89%). The adjusted hazard ratio for AI within  the first year differed significantly between the two groups with the HL group having a 50 percent higher risk of all infections (HR: 1.51; 95% CI: 1.14, 2.01).

The most common types of AI in the HL group were lower (34%) and upper (16%) respiratory tract infections, urinary tract infections (15%), skin infections including shingles (8%).

Serious inffections, however, were not increased with high vs. low doses of biologic exposure. 

This study suggests that monitoring drug levels may be helpful in prediction of infectious complications in RA patients.

Biologic dose tapering in patients with high biologic levels who were able to achieve stable remission may lower infection risk.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

IL-6 for Adult Still's: A New Option?

Some clinical benefits were seen among patients with adult-onset Still's disease treated with tocilizumab (Actemra) in a small clinical trial, but the study's primary endpoint was not met, Japanese researchers reported.

Unproven But Profitable Stem Cell Clinics

Stem cell clinics are popular and proliferating as they are largely a cash business and fall outside of FDA regulatory control. In lieu of scientific proof, most advocates use patient testimonials and the placebo effect to back up their claims.

Out of Pocket Costs for Biosimilars - No Savings So Far

JAMA has published an analysis showing that under Medicare Part D, RA biosimilar infliximab-dyyb was only moderately less expensive (18% less) than the biologic infliximab and, owing to differences in gap discounts, the out of pocket costs for the biosimilar was nearly $1700 more than infliximab in 2017.

Cutting Oral JAK 1/2 Inhibitor Dose an Option in RA

Many patients with rheumatoid arthritis (RA) who achieved sustained disease control with baricitinib (Olumiant) treatment were able to reduce their daily dose from 4 mg to 2 mg and maintain their response, a double-blind substudy of a long-term extension trial found.

Tocilizumab Equals other Biologics in Cardiovascular Risk

An odd side effect of several new agents is the risk of hyperlipidemia. While this has been seen with tocilizumab (TCZ), there does not appear to be a resultant risk of cardiovascular (CV) events. A study of claims data compared CV risk in rheumatoid arthritis (RA) patients receiving TOC (an IL6 receptor antagonists) and other biologics and found no differences with regard to CV outcomes.